Good Life Advisors LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Good Life Advisors LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 19,276 shares of the medical device company’s stock, valued at approximately $2,477,000.

Other institutional investors have also added to or reduced their stakes in the company. Resources Investment Advisors LLC. bought a new position in shares of DexCom in the 1st quarter worth $287,000. Financial Counselors Inc. lifted its stake in shares of DexCom by 2.3% in the first quarter. Financial Counselors Inc. now owns 27,189 shares of the medical device company’s stock valued at $3,159,000 after buying an additional 615 shares in the last quarter. Spouting Rock Asset Management LLC acquired a new position in shares of DexCom during the first quarter valued at about $540,000. First Hawaiian Bank increased its position in shares of DexCom by 0.9% during the first quarter. First Hawaiian Bank now owns 15,923 shares of the medical device company’s stock worth $1,850,000 after acquiring an additional 149 shares in the last quarter. Finally, CX Institutional acquired a new stake in shares of DexCom in the 1st quarter worth about $251,000. 93.88% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, Director Steven Robert Pacelli sold 5,031 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $136.00, for a total value of $684,216.00. Following the sale, the director now owns 126,831 shares of the company’s stock, valued at $17,249,016. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Steven Robert Pacelli sold 5,031 shares of DexCom stock in a transaction on Friday, July 14th. The stock was sold at an average price of $136.00, for a total value of $684,216.00. Following the completion of the transaction, the director now directly owns 126,831 shares in the company, valued at $17,249,016. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jereme M. Sylvain sold 1,844 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $104.38, for a total value of $192,476.72. Following the sale, the chief financial officer now owns 72,867 shares in the company, valued at $7,605,857.46. The disclosure for this sale can be found here. Insiders have sold a total of 9,550 shares of company stock valued at $1,189,620 over the last three months. 0.41% of the stock is currently owned by insiders.

DexCom Price Performance

DexCom stock opened at $96.35 on Friday. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 1.16. The business’s 50 day simple moving average is $115.60 and its 200 day simple moving average is $118.23. DexCom, Inc. has a 12 month low of $78.94 and a 12 month high of $139.55. The company has a market cap of $37.37 billion, a price-to-earnings ratio of 112.03, a PEG ratio of 1.99 and a beta of 1.12.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.12. DexCom had a return on equity of 22.01% and a net margin of 11.18%. The firm had revenue of $871.30 million for the quarter, compared to analysts’ expectations of $841.16 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The business’s revenue for the quarter was up 25.2% compared to the same quarter last year. Sell-side analysts forecast that DexCom, Inc. will post 1.23 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on DXCM. Morgan Stanley started coverage on DexCom in a research note on Tuesday, May 30th. They set an “equal weight” rating and a $131.00 price target for the company. Piper Sandler increased their price target on DexCom from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, July 28th. StockNews.com started coverage on shares of DexCom in a report on Thursday, August 17th. They set a “hold” rating on the stock. Raymond James lowered their target price on shares of DexCom from $154.00 to $131.00 and set a “strong-buy” rating for the company in a report on Friday. Finally, Robert W. Baird cut their price target on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating on the stock in a report on Monday, August 21st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $136.31.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.